Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Adaptive Biotechnologies (ADPT) stock in plain English

Free brief · no signupStart here
ADPTPublished Nov 18, 2026
Adaptive Biotechnologies Corp
Healthcare · Diagnostics & Research
Sells diagnostic tests that measure residual blood cancer cells and immune profiling services for pharmaceutical drug discovery.
Assets:
clonoSEQ assayFDA-cleared test measuring minimal residual disease in lymphoid cancers
immunoSEQ serviceSequencing technology providing immune cell data to clinical researchers
Seattle laboratoryCLIA-certified clinical genomics testing facility in Washington State
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

49
OPS ScoreOperating finances
Latest quote
-1.44%$28.05
$4.54B
n/a (loss)
$297.94M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was ADPT. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Adaptive Biotechnologies (ADPT) do?

Adaptive Biotechnologies Corp (ADPT) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Sells diagnostic tests that measure residual blood cancer cells and immune profiling services for pharmaceutical drug discovery. Sequences adaptive immune receptors to decode individual immune responses for clinical diagnostics and drug discovery. It is worth $4.54B on the market and sold $297.94M over the last year.

Market cap
$4.54B
P/E ratio
None (reported a loss)
Annual sales
$297.94M
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 18, 2026

Brands and businesses behind ADPT

  • clonoSEQ: A diagnostic test that generates revenue by billing insurers for measuring leftover cancer cells in patients.
  • immunoSEQ: An immune profiling platform that earns fees by sequencing immune cell receptors for pharmaceutical research clients.

ADPT’s flags, in plain English

Each flag is a number from Adaptive Biotechnologies’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Wide Gross Margin

Gross margin of 71.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Stupid Cash

Can pay this year's bills 4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Still Climbing

Sales up 23% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Debt Is Driving

Heavy debt, 232% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

1 more risk note open with the free trial. Try it free for 7 days.

Questions about ADPT

How big is Adaptive Biotechnologies?

Adaptive Biotechnologies’ market cap is $4.54B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $297.94M: what customers paid the company over the last year, before any costs.

What is ADPT’s P/E ratio?

ADPT has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with ADPT?

The company continues to lose money each year and generates negative cash flow from operations. That is one risk on Adaptive Biotechnologies’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Adaptive Biotechnologies’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ADPT’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card